GLP-1 Face: Why Facial Hollowing Occurs and What You Can Do

“GLP-1 face” refers to the facial volume changes — hollowing in the cheeks, temples, or under the eyes — that some people notice during weight loss on a GLP-1 receptor agonist medication. Current research points toward the weight loss process itself, rather than a direct pharmacological action of the medication on facial tissue, as the primary associated factor — though this distinction is not yet fully settled in the published literature. This article covers the underlying anatomy, what the research currently suggests about mechanism, and how to track these changes for provider conversations.

What Is “GLP-1 Face”?

“GLP-1 face” is an informal term used in medical commentary and online communities to describe changes in facial appearance that some people notice while losing weight on a GLP-1 receptor agonist medication. It is not a medical diagnosis, and the experience varies considerably between individuals.

Some people describe their face as appearing more hollowed, drawn, or aged during the weight loss process — noting a contrast where the body looks slimmer while the face looks older or more gaunt. This kind of observation reflects a real experience that some people report, though how noticeable these changes are depends on many individual factors.

The facial changes most commonly described involve volume loss in the cheeks, temples, and the area around and beneath the eyes. These regions are supported by subcutaneous fat compartments — layers of fat just beneath the skin that give the face much of its structural fullness and shape. When these compartments lose volume during weight loss, the overlying skin has less structural support to rest against, which can change how the face looks and feels.

A 2025 systematic review by Daneshgaran, Shauly, and Gould — examining the published literature on GLP-1 receptor agonist–related facial changes — identified the temporal region, the cheeks, and the periorbital area as among those most commonly described in reports of GLP-1 face. The review also noted that changes in collagen and elastin have been observed in analyses of skin in this context, though the relationship between GLP-1 receptor agonist use specifically, as distinct from weight loss itself, and these tissue changes remains an active area of investigation.

What GLP-1 face is not: it is not a sign of organ damage, an allergic response, or a reason to stop a medication without consulting a provider. Facial volume changes during significant weight loss are a reported experience — not a danger signal, though worth discussing with a provider if they concern you.

For skin surface changes during GLP-1 use — such as dryness, acne, or rash — those are covered separately in GLP-1 and Skin Changes.

Why Facial Fat Matters for Structure and Appearance

The face is supported by several anatomical layers: bone, muscle, deep fat compartments, subcutaneous fat, and skin. Subcutaneous fat — particularly in the temporal region (temples), the malar region (cheeks), and the periorbital region (under and around the eyes) — functions as structural scaffolding for the skin above it. This fat is not simply cosmetic padding; it provides the volume and support that gives the face much of its three-dimensional shape.

A 2026 narrative review by Frank et al. on the anatomical mechanisms related to GLP-1–induced weight loss described this scaffolding role: discrete facial fat compartments provide volume support for the overlying skin. When the volume in these compartments decreases, the skin has less structure to rest against, and the visible result depends on how much the skin can contract or redrape over the changed underlying anatomy.

The skin’s capacity to contract after fat volume loss depends on its baseline elasticity — which is partly a function of age and genetics. Skin with more robust collagen and elastin tends to retract more fully after a reduction in the underlying fat; skin with reduced elasticity may show more visible laxity or hollowing.

This relationship between facial fat compartments and facial appearance is not unique to GLP-1 medication use. Similar facial changes have been described in people who have lost substantial weight through bariatric surgery, sustained dietary changes, or illness — contexts where subcutaneous fat compartments also change in volume. What may be distinctive about GLP-1–related weight loss for some people is the pace at which weight loss can occur, compressing the timeline in which these compartment changes happen.

Why the Rate of Weight Loss Affects How the Face Responds

The rate of weight loss appears in the medical literature as one factor associated with how visible facial volume changes become. This is not a recommendation about the speed of weight loss — that is a clinical decision made between a patient and their provider. What follows describes why the rate appears to matter mechanically.

Skin has a degree of elasticity that allows it to contract gradually as the structures beneath it change. This process takes time. When significant weight loss occurs over a shorter period, the reduction in subcutaneous fat compartment volume may outpace the skin’s capacity to adapt, potentially resulting in more visible laxity or hollowing. When weight loss occurs more gradually, the skin may have more opportunity to remodel alongside the changing fat compartments — though individual variation in baseline skin quality, age, and genetics means outcomes differ considerably between people.

A 2025 review by Haykal, Hersant, Cartier, and Meningaud, examining the role of GLP-1 agonists in aesthetic medicine, noted that skin retraction capacity varies significantly depending on age, genetics, and rate of weight loss — and specifically identified the long-term effects on collagen, elastin, and other extracellular matrix components as an area where more research is needed.

The rate of weight loss on a GLP-1 receptor agonist is managed as part of a provider-supervised treatment plan. If the pace of change or its visible effects are a concern, that is a reason to raise it with a provider directly — not a reason to self-adjust medication use.

Which Areas of the Face Tend to Change Most

The areas most commonly described in clinical reports and patient accounts involve specific fat compartments:

Temples (temporal region): The temporal fat pad, located at the sides of the forehead and upper face, is among the areas more frequently noted in descriptions of GLP-1 face. Some people describe the temples appearing more sunken or hollow, with the underlying bony structure becoming more visible.

Cheeks (malar region): The malar fat compartments support the fullness of the mid-face. Some people describe noticing their cheeks becoming less full — in some accounts, the change appears more sudden than gradual. The buccal fat pad, a deeper compartment of the cheek, may also be involved, though its specific role in GLP-1–related facial changes is less established.

Under and around the eyes (periorbital region): The periorbital fat compartments support the area surrounding the eyes. When volume decreases in this region, the area can appear more hollowed, and the underlying bone structure or vasculature may become more visible than before.

A 2025 review by Kruglikov on the mechanisms of GLP-1 receptor agonist–related facial changes proposed that the facial fat compartments — including the temporal and malar regions — may experience volume reduction that is disproportionate to overall body fat loss. This is a proposed mechanistic hypothesis derived from a very small number of cases; it is an area of ongoing investigation, not an established finding.

Not everyone who uses a GLP-1 receptor agonist will notice facial changes. Individual factors — including total weight lost, rate of loss, baseline skin elasticity, age, and anatomy — all appear to influence whether and how much facial change occurs.

How Collagen and Skin Support Structures Are Involved

Collagen and elastin are structural proteins in the skin’s extracellular matrix that provide firmness and elasticity. The skin’s ability to retract after fat volume loss depends partly on the integrity and density of these proteins, which naturally decline with age and can be affected by significant changes in body composition.

The systematic review by Daneshgaran, Shauly, and Gould (2025) noted that changes in collagen and elastin have been identified in analyses of skin associated with GLP-1–related weight loss. However, the review also documented a meaningful gap in the literature: whether these changes result from the effects of weight loss itself, from a direct action of the medication on skin tissue, or from some combination of factors remains unclear from the current evidence.

The review by Haykal, Hersant, Cartier, and Meningaud (2025) similarly identified the effects on extracellular matrix components — including collagen and elastin — as an area where longitudinal research is needed to understand the skin’s structural response to GLP-1–associated weight loss over time.

The skin’s structural response to weight loss is highly individual. Two people losing a similar amount of weight over a similar period may have very different experiences of facial change — a reminder that descriptions of GLP-1 face reflect a range of experiences, not a single predictable outcome.

Specific recommendations about nutrition, supplements, or skin care in the context of collagen support are outside the scope of this article. Those questions are best addressed by a provider or registered dietitian familiar with an individual’s full situation.

Is This the Medication, or the Weight Loss?

This is among the most commonly asked questions about GLP-1 face — and one that receives less attention in many overviews of the topic than it deserves.

The short answer: Current research points toward the weight loss process as the primary associated factor, rather than a direct pharmacological action of GLP-1 receptor agonists on facial fat tissue specifically.

The table below summarizes what current evidence points to and what remains unestablished:

The narrative review by Frank et al. (2026) framed the facial changes associated with GLP-1–induced weight loss primarily in terms of weight-loss–driven anatomical changes: fat compartment volume reduction during significant weight loss leads to structural changes in facial appearance, through the same mechanism that produces facial changes in other forms of significant weight loss.

Why does this distinction matter? If facial changes are primarily driven by the weight loss process rather than a direct medication effect, this reshapes how the experience is understood:

• People who have lost significant weight through other means may have experienced comparable facial changes — the phenomenon is not exclusive to GLP-1 medication use
• The conversation with a provider shifts from “is this medication affecting my face?” to “how does the rate and extent of weight loss affect my appearance, and what options are available if I want to discuss it?”
• Decisions about medication — including whether to continue, modify the approach, or discuss the pace of weight loss — remain in the domain of provider-supervised care, not appearance management

This does not minimize the experience. Facial appearance matters to people, and noticing visible changes in how one looks is real. The research simply points toward weight loss as the primary mechanism — not toward the medication producing facial changes that would not occur with equivalent weight loss through other means.

For related context on medication mechanisms, see How GLP-1 Medications Work.

What to Log About Facial Changes

If you are noticing changes in your facial appearance while on a GLP-1 receptor agonist, keeping a record of those observations can make provider conversations more productive. The GLP-1 Side-Effect and Progress Tracker allows you to log facial and other changes alongside the rest of what you are tracking.

Track Your Progress with the GLP-1 Tracker

Observations worth noting:

• When the changes appeared — relative to when you started the medication or when noticeable weight loss began
• Which areas seem most different — temples, cheeks, under the eyes, or other areas you notice
• What else was happening at the same time — overall weight, rate of loss, any changes in sleep, hydration, or general health
• Your own description of what you observe — your words help a provider understand the experience, especially if you can note how observations change over time

If you are already seeing a dermatologist, primary care provider, or any specialist, facial changes during GLP-1 use are worth mentioning. A provider who can assess you in person has much more context than any written resource.

If facial changes are accompanied by other symptoms that concern you — difficulty swallowing, unexplained swelling, pain, or anything that feels sudden — contact a provider promptly. For a medical emergency, call 911 or your local emergency services.

Related tracking and reference topics:

• GLP-1 and Muscle Loss
• GLP-1 and Hair Loss
• GLP-1 Side Effects: When to Call Your Doctor
• GLP-1 Side Effects Overview